ADIL Stock Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Adial Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$0.77 |
| Beta | 1.53 |
| 1 Month Change | 46.02% |
| 3 Month Change | 42.24% |
| 1 Year Change | -79.30% |
| 3 Year Change | -96.78% |
| 5 Year Change | -97.07% |
| Change since IPO | -98.37% |
Recent News & Updates
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Shareholder Returns
| ADIL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.8% | 1.4% | 2.7% |
| 1Y | -79.3% | 12.9% | 26.0% |
Return vs Industry: ADIL underperformed the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: ADIL underperformed the US Market which returned 25% over the past year.
Price Volatility
| ADIL volatility | |
|---|---|
| ADIL Average Weekly Movement | 46.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ADIL's share price has been volatile over the past 3 months.
Volatility Over Time: ADIL's weekly volatility has increased from 29% to 47% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6 | Cary Claiborne | www.adialpharma.com |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. Fundamentals Summary
| ADIL fundamental statistics | |
|---|---|
| Market cap | US$6.45m |
| Earnings (TTM) | -US$7.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs ADIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADIL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.00m |
| Earnings | -US$7.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ADIL perform over the long term?
See historical performance and comparison